logo
  Join        Login             Stock Quote

ISIS Pharmaceuticals (ISIS) Tumbles After CHMP Adopts Negative Opinion On Kynamro

 December 14, 2012 08:13 AM
 


(By Balachander) ISIS Pharmaceuticals Inc. (NASDAQ: ISIS) shares tumbled in Friday premarket trading after an European Committee recommended the refusal of the marketing authorisation for its lead product Kynamro intended to treat high blood cholesterol levels, citing saftety concerns.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on Thursday adopted a negative opinion for Kynamro for the treatment of patients with an inherited disease causing high blood cholesterol levels, called familial hypercholesterolaemia.

The CHMP was of the opinion that the benefits of Kynamro did not outweigh its risks and recommended that it be refused marketing authorisation.

[Related -Futures Down Ahead Of Service Sector Data; Compugen Ltd. (CGEN) Soars]

The Committee noted that a high proportion of patients stopped taking the medicine within two years, mainly due to side effects such as flu-like symptoms, injections site reactions and liver toxicity. The Committee was also concerned that a greater proportion of patients taking Kynamro experienced serious cardiovascular events (problems with the heart and blood vessels) than patients taking placebo.

"This prevented the CHMP from concluding that Kynamro's intended cardiovascular benefit, in terms of reducing cholesterol levels, outweighed its cardiovascular risk," CHMP said.

Genzyme, a Sanofi company (NYSE: SNY) and ISIS' partner, plans to request a re-examination of the CHMP Opinion.

[Related -Futures Down On China Worries; Vanguard Health Systems Inc. (VHSSurge]

In October 2012, KYNAMRO received a positive vote by an U.S. Food and Drug Administration (FDA) advisory panel that Genzyme had provided sufficient efficacy and safety data to support the marketing of KYNAMRO to treat HoFH.

ISIS shares dropped 8.95 percent in Friday pre-market trade.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.